Triple-negative breast cancer

Rafael Rosell*, Maria Luisa Botero, María González Cao, Mirea Margeli, Agustí Barnadas, Maria Teresa Cusido, Rafael Fabregas, Carlota Costa, Ana Gimenéz-Capitán, Mariacarmela Santarpia, Susana Benlloch

*Autor corresponent d’aquest treball

Producció científica: Capítol de llibreCapítolRecercaAvaluat per experts

2 Cites (Scopus)

Resum

Triple-negative breast cancer (TNBC) is a subclass of breast cancer and a heterogeneous disease that includes basal-like and claudin-low tumors. Claudin-low tumors are enriched for features associated with epithelial-to-mesenchymal transition (EMT) [1] and possibly for tumor initiating cells [2,3]. Some authors prefer the classification of ‘triple-negative-basal-like’ and ‘triple-negative-non-basal’. Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in females worldwide, accounting for 23% (1.38 million) of total new cancer cases and 14% (458,400) of total cancer deaths in 2008 [4]. Approximately 15–30% of women with breast cancer have TNBC [2,3].
Idioma originalAnglès
Títol de la publicacióMolecular-Based Decision Making for Personalized Cancer Management
Lloc de publicacióLondon
EditorFuture Medicine Ltd.
Pàgines75-88
Nombre de pàgines14
ISBN (electrònic)9781780841533
ISBN (imprès)9781780841557
DOIs
Estat de la publicacióPublicada - de set. 2012

Fingerprint

Navegar pels temes de recerca de 'Triple-negative breast cancer'. Junts formen un fingerprint únic.

Com citar-ho